Sichuan Biokin Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A carries a market capitalization of 121.40B, placing it among publicly traded companies globally. Its enterprise value stands at 121.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sichuan Biokin Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A has 412.87M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 161.47, and the price-to-book ratio stands at 26.33.

These figures are as of June 30, 2026. The EV/Sales ratio of 163.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 121.62B versus a market cap of 121.40B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A maintains a current ratio of 4.23, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 113.79, indicating elevated leverage, while an interest coverage ratio of -27.85 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -69.73, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -30.09, reflecting losses generated across the asset base. The company generates approximately 246,078.57 in revenue per employee across its workforce of 3,028.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.32 indicates how many times Sichuan Biokin Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A recorded an income tax benefit of -19.67M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -2.80B and -2.78B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A's stock has declined approximately 28.73% over the past 52 weeks. The 50-day moving average sits at 261.04, while the 200-day moving average is 278.17.

Over the twelve months ended June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A generated 745.31M in revenue and converted that into -2.78B in net income, yielding earnings per share of -6.80. EBITDA reached -2.79B, while operating income came in at -2.75B.

As of June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A holds 5.03B in cash and equivalents against 5.25B in total debt, resulting in a net debt position of 379.17M. Total book value stands at 4.61B, with working capital of 7.50B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A posted a gross margin of 68.21, reflecting its pricing power and cost economics. The operating margin of -369.00 and net profit margin of -373.38 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A paid dividends of 0.22 per share. The dividend payout ratio of -3.22 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -1.01, meaning Sichuan Biokin Pharmaceutical Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Sichuan Biokin Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 11.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.